title: Glutamatergic and serotonergic mechanisms in the dorsal facial area for common carotid artery blood flow control in the cat.
abstract: This study explored which subtyes of glutamate receptors in the dorsal facial area are involved in the interaction between glutamatergic and serotonergic actions in controlling common carotid arterial blood flow. Microinjection of glutamate (25-100 nmol), N-methyl-D-aspartate (NMDA; 1-4 nmol), or alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA; 0.5-2 nmol) into the dorsal facial area dose-dependently increased common carotid arterial blood flow. The potency order was AMPA>NMDA>glutamate. The glutamate-induced increase in common carotid arterial blood flow was reduced by pretreatment with either D-2-amino-5-phosphonopentanoate (D-AP5; 2.5-5.0 nmol), or glutamate diethylester (25-50 nmol). The common carotid arterial blood flow was increased by ketanserin (1.0 nmol) and decreased by (+/-)-1-(2, 5-dimethoxy-4-iodophenyl)-2-aminopropane (1.0 nmol). Both effects were attenuated by pretreatment with either D-AP5 or glutamate diethylester. We conclude that activation of both NMDA and AMPA receptors in dorsal facial area is responsible for the increase in common carotid arterial blood flow, and AMPA receptor may play a greater role. Such response may be suppressed by 5-HT2 action.
authors.affiliation: Department of Physiology, School of Medicine, China Medical College, Taichung, Taiwan, ROC.
authors.forename: Chi-Li
authors.initials: CL
authors.lastname: Gong
authors.forename: Nai-Nu
authors.initials: NN
authors.lastname: Lin
authors.forename: Jon-Son
authors.initials: JS
authors.lastname: Kuo
mesh_terms: D015763:2-Amino-5-phosphonovalerate / Q000494:pharmacology; D000662:Amphetamines / Q000494:pharmacology; D000818:Animals; D001783:Blood Flow Velocity / Q000187:drug effects; D001794:Blood Pressure / Q000187:drug effects; D017536:Carotid Artery, Common / Q000187:drug effects* / Q000502:physiology; D002415:Cats; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D018690:Excitatory Amino Acid Agonists / Q000494:pharmacology; D018691:Excitatory Amino Acid Antagonists / Q000494:pharmacology; D018846:Excitatory Amino Acids / Q000494:pharmacology; D005260:Female; D005971:Glutamates / Q000494:pharmacology; D018698:Glutamic Acid / Q000494:pharmacology; D006339:Heart Rate / Q000187:drug effects; D007650:Ketanserin / Q000494:pharmacology; D008297:Male; D008526:Medulla Oblongata / Q000098:blood supply / Q000187:drug effects* / Q000502:physiology; D008845:Microinjections / Q000379:methods; D016202:N-Methylaspartate / Q000494:pharmacology; D018091:Receptors, AMPA / Q000819:agonists / Q000037:antagonists & inhibitors; D012702:Serotonin Antagonists / Q000494:pharmacology; D017366:Serotonin Receptor Agonists / Q000494:pharmacology; D018350:alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid / Q000494:pharmacology
chemical_list: D000662:Amphetamines; D018690:Excitatory Amino Acid Agonists; D018691:Excitatory Amino Acid Antagonists; D018846:Excitatory Amino Acids; D005971:Glutamates; D018091:Receptors, AMPA; D012702:Serotonin Antagonists; D017366:Serotonin Receptor Agonists; D018698:Glutamic Acid; D016202:N-Methylaspartate; C035873:glutamic acid dimethyl ester; D015763:2-Amino-5-phosphonovalerate; D018350:alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; D007650:Ketanserin; C015952:4-iodo-2,5-dimethoxyphenylisopropylamine